02-22-08 - Elixir Pharmaceuticals, Inc., announced new data on the role of ghrelin antagonism in the regulation of metabolism and as a potential treatment for Type 2 diabetes. The data were presented by Dr. Yong Qi in a platform session during Keystone Symposia’s Neuronal Mechanisms Controlling Food Intake, Glucose Metabolism and Body Weight meeting being held this week in Banff, Alberta, Canada. Elixir’s small molecule ghrelin antagonists derive from the Company’s focus on pathways involved in the regulation of aging. Elixir identifies novel targets in these pathways leading to the development of compounds to treat a range of diseases of aging, including metabolic diseases such as diabetes and obesity... [PDF] Elixir Pharmaceuticals' Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
March
(40)
- Medtronic : Announces Sales Milestone of One Milli...
- AgaMatrix : WaveSense Europe Launches Jazz Glucose...
- Boston Scientific : TAXUS Express Stent Shows Simi...
- SemBioSys : toxicology study for safflower-produce...
- Keryx Biopharmaceuticals : Termination of SUN-MACR...
- Atherotech 's VAP Test Helps Researchers Uncover B...
- Generex Biotechnology : Its Protocol for Metcontr...
- Echo Therapeutics : Positive Results from Symphony...
- Oramed Pharmaceuticals : Phase 2A Trials of Its Or...
- MacroChem, Pexiganan Phase 3 Study Results for Top...
- MannKind : Response to Recent Market Events
- Generex Oral-lyn, another regulatory approval to c...
- Metabolon and EGIR, Partnership to Accelerate Pre-...
- Mercury Therapeutics : series of indirect AMPK act...
- Sirtris' SIRT1 Activators; Patent Covers First NCE...
- DiObex and Camurus , Agreement for the Development...
- Lilly and Transition Therapeutics, Licensing and C...
- Synvista Therapeutics, Newly Published Data Demons...
- PPD, Takeda's NDA Filing of Alogliptin with U.S. F...
- Alizyme's cetilistat Phase III development program...
- Axis-Shield, HbA1c Test on Abbott's AXSYM Analyser
- Marcadia Biotech and Merck, strategic collaboration
- OSI Pharmaceuticals : the Prior Revocation of Its ...
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Diamyd Medical, Authorization to Begin Phase III S...
- Sernova, First Regulatory Step Towards Clinical Tr...
- Cannasat Therapeutics, Update on Patent Applicatio...
- Living Cell Technologies' DiabeCell Clinical Trial...
- Nitric BioTherapeutics, Phase II Clinical Trial fo...
- Oramed Pharmaceuticalsals, Phase 1B Clinical Trial...
- Abbott's FreeStyle Navigator Continuous Glucose Mo...
- Elixir Pharmaceuticals, new data on the role of gh...
- Akesis Pharmaceuticals, First Patient in Phase IIa...
- Oculus Innovative Sciences, Phase II Data with Mic...
- Alkermes, Eli Lilly, Termination of AIR (Inhaled) ...
- PLC Systems' RenalGuard Therapy and RenalGuard Sys...
- Novocell, Successful Use of Stem Cells to Generate...
- Novartis Eucreas combination of Galvus® and metfor...
- Johnson & Johnson Diabetes Institute, New Center T...
- Metabasis Therapeutics, Proof-of-Concept Clinical ...
-
▼
March
(40)
Monday, March 10, 2008
Elixir Pharmaceuticals, new data on the role of ghrelin antagonism in the regulation of metabolism and as a potential treatment for Type 2 diabetes
Libellés :
Elixir Pharmaceuticals,
Type 2 Diabetes